The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
Open accessAbstract
Intravenous infusion of oncolytic reovirus in patients leads to infection of brain tumors, infiltration by cytotoxic T cells, and up-regulation of PD-L1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,116
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 13×
“V. Kasprowicz, J. Schulze Zur Wiesch, T. Kuntzen, B. E. Nolan, S. Longworth, A. Berical, J. Blum, C. McMahon, L. L. Reyor, N. Elias, W. W. Kwok, B. G. McGovern, G. Freeman, R. T. Chung, P. Klenerman, L. Lewis-Ximenez, B. D. Walker, T. M. Allen, A. Y. Kim, G. M. Lauer, High level of PD-1 expression on hepatitis C virus…”
BackgroundInfluentialNivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
Self-citationOncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013
Wang, J., Duncan, D., Shi, Z., & Zhang, B. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt439 · Cited by 1,498
Gooden, M. J. M., de Bock, G. H., Leffers, N., Daemen, T., & Nijman, H. W. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.189 · Cited by 1,277
Markert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D., Palmer, C. A., Feigenbaum, F., Tornatore, C., Tufaro, F., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301205 · Cited by 976
Antitumour actions of interferons: implications for cancer therapy
Parker, B. S., Rautela, J., & Hertzog, P. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.14 · Cited by 907
INTERFEROME v2.0: an updated database of annotated interferon-regulated genes
Rusinova, I., Forster, S., Yu, S., Kannan, A., Masse, M., Cumming, H., Chapman, R., & Hertzog, P. J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1215 · Cited by 878
Castellino, F., Huang, A. Y., Altan-Bonnet, G., Stoll, S., Scheinecker, C., & Germain, R. N. (2006) · Nature · doi:10.1038/nature04651 · Cited by 855
Rampling, R., Cruickshank, G., Papanastassiou, V, Nicoll, J., Hadley, D., Brennan, D., Petty, R., MacLean, A., Harland, J., McKie, E., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301184 · Cited by 598
PD-L1 expression and prognostic impact in glioblastoma
Nduom, E. K., Wei, J., Yaghi, N. K., Huang, N., Kong, L.-Y., Gabrusiewicz, K., Ling, X., Zhou, S., Ivan, C., Chen, J. Q., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov172 · Cited by 596
Chiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., Kracher, J., Grossman, S. A., Fisher, J. D., Carson, K., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.021 · Cited by 436
Wu, L., LaRosa, G., Kassam, N., Gordon, C. J., Heath, H., Ruffing, N., Chen, H., Humblias, J., Samson, M., Parmentier, M., et al. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.8.1373 · Cited by 357
Harrow, S., Papanastassiou, V, Harland, J., Mabbs, R., Petty, R., Fraser, M., Hadley, D., Patterson, J., Brown, S. M., & Rampling, R. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302289 · Cited by 342
Papanastassiou, V, Rampling, R., Fraser, M., Petty, R., Hadley, D., Nicoll, J., Harland, J., Mabbs, R., & Brown, M. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301664 · Cited by 328
Molecular mechanisms of brain tumor edema
Papadopoulos, M. C., Saadoun, S., Binder, D. K., Manley, G. T., Krishna, S., & Verkman, A. S. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.05.044 · Cited by 308
Parato, K. A., Breitbach, C. J., Le Boeuf, F., Wang, J., Storbeck, C., Ilkow, C., Diallo, J.-S., Falls, T., Burns, J., Garcia, V., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.276 · Cited by 305
Bourgeois-Daigneault, M.-C., Roy, D. G., Aitken, A. S., El Sayes, N., Martin, N. T., Varette, O., Falls, T., St-Germain, L. E., Pelin, A., Lichty, B. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao1641 · Cited by 293
Forsyth, P., Roldán, G., George, D., Wallace, C., Palmer, C. A., Morris, D., Cairncross, G., Matthews, M. V., Markert, J., Gillespie, Y., et al. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300403 · Cited by 278
Self-citationA Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer
Vidal, L., Pandha, H. S., Yap, T. A., White, C. L., Twigger, K., Vile, R. G., Melcher, A., Coffey, M., Harrington, K. J., & DeBono, J. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0524 · Cited by 237
Self-citationThunder and Lightning: Immunotherapy and Oncolytic Viruses Collide
Melcher, A., Parato, K., Rooney, C. M., & Bell, J. C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.65 · Cited by 232
Self-citationKasprowicz, V., Schulze zur Wiesch, J., Kuntzen, T., Nolan, B. E., Longworth, S., Berical, A., Blum, J., McMahon, C., Reyor, L. L., Elias, N., et al. (2008) · Journal of Virology · doi:10.1128/jvi.02474-07 · Cited by 202
Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients
Adair, R. A., Roulstone, V., Scott, K. J., Morgan, R., Nuovo, G. J., Fuller, M., Beirne, D., West, E. J., Jennings, V. A., Rose, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003578 · Cited by 192
Self-citationParker, J. S. L., Broering, T. J., Kim, J., Higgins, D. E., & Nibert, M. L. (2002) · Journal of Virology · doi:10.1128/jvi.76.9.4483-4496.2002 · Cited by 188
Rajani, K., Parrish, C., Kottke, T., Thompson, J., Zaidi, S., Ilett, L., Shim, K. G., Diaz, R.-M., Pandha, H., Harrington, K., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2015.156 · Cited by 182
Self-citationUtility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Diggs, L. P., & Hsueh, E. C. (2017) · Biomarker Research · doi:10.1186/s40364-017-0093-8 · Cited by 173
ICAM-1: Getting a Grip on Leukocyte Adhesion
Long, E. O. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100646 · Cited by 168
Role of PD-1 in regulating acute infections
Brown, K. E., Freeman, G. J., Wherry, E. J., & Sharpe, A. H. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.03.007 · Cited by 160
Geletneky, K., Huesing, J., Rommelaere, J., Schlehofer, J. R., Leuchs, B., Dahm, M., Krebs, O., Doeberitz, M. V. K., Huber, B., & Hajda, J. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-99 · Cited by 159
Kicielinski, K. P., Chiocca, E. A., Yu, J. S., Gill, G. M., Coffey, M., & Markert, J. M. (2014) · Molecular Therapy · doi:10.1038/mt.2014.21 · Cited by 158
Self-citationMonoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier
Lampson, L. A. (2011) · mAbs · doi:10.4161/mabs.3.2.14239 · Cited by 152
An RNAi Screen Identifies TRRAP as a Regulator of Brain Tumor-Initiating Cell Differentiation
Wurdak, H., Zhu, S., Romero, A., Lorger, M., Watson, J., Chiang, C.-Y., Zhang, J., Natu, V. S., Lairson, L. L., Walker, J. R., et al. (2010) · Cell stem cell · doi:10.1016/j.stem.2009.11.002 · Cited by 149
Self-citationYau, T. C. C., Swanton, C., Chua, S. C., Sue, A., Walsh, G., Rostom, A. Y., Johnston, S. R. D., O'Brien, M. E. R., & Smith, I. E. (2006) · Acta Oncologica · doi:10.1080/02841860500486630 · Cited by 142
Benencia, F., Courreges, M. C., Conejo-Garcia, J. R., Mohamed-Hadley, A. A., Zhang, L., Buckanovich, R. J., Carroll, R. H., Fraser, N. W., & Coukos, G. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.026 · Cited by 127
Braun, N., Papadopoulos, T., & Müller‐Hermelink, H. K. (1988) · Virchows Archiv B Cell Pathology Including Molecular Pathology · doi:10.1007/bf02889998 · Cited by 119
Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma
Errington‐Mais, F., White, C. L., Twigger, K. R., Rose, A., Scott, K. J., Steele, L. P., Ilett, E. J., Prestwich, R. J. D., Pandha, H. S., Coffey, M. C., et al. (2008) · Gene Therapy · doi:10.1038/gt.2008.58 · Cited by 115
Self-citationSteele, L. P., Errington‐Mais, F., Prestwich, R. J. D., Ilett, E. J., Harrington, K. J., Pandha, H., Coffey, M. C., Selby, P. J., Vile, R. G., & Melcher, A. A. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-20 · Cited by 81
Self-citationCytokine Conditioning Enhances Systemic Delivery and Therapy of an Oncolytic Virus
Ilett, E. J., Kottke, T. J., Donnelly, O., Thompson, J., Willmon, C. L., Díaz, R. M., Zaidi, S., Coffey, M. C., Selby, P. J., Harrington, K. J., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.118 · Cited by 75
Self-citationDefining the Chemokine Basis for Leukocyte Recruitment during Viral Encephalitis
Michlmayr, D., McKimmie, C. S., Pingen, M., Haxton, B., Mansfield, K. L., Johnson, N., Fooks, A. R., & Graham, G. J. (2014) · Journal of Virology · doi:10.1128/jvi.03421-13 · Cited by 56
Nuovo, G. J., Garofalo, M., Valeri, N., Roulstone, V., Volinia, S., Cohn, D. E., Phelps, M. A., Harrington, K. J., Vile, R. G., Melcher, A. A., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.95 · Cited by 52
Self-citationConway, C., Graham, J. L., Chengot, P., Daly, C. L., Chalkley, R., Ross, L., Droop, A., Rabbitts, P. H., & Stead, L. F. (2015) · Oncotarget · doi:10.18632/oncotarget.5529 · Cited by 46
Self-citationLapa, C., Linsenmann, T., Lückerath, K., Samnick, S., Herrmann, K., Stoffer, C., Ernestus, R., Buck, A. K., Löhr, M., & Monoranu, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122269 · Cited by 45
Cited by
Achrol, A. S., Rennert, R. C., Anders, C., Soffietti, R., Ahluwalia, M. S., Nayak, L., Peters, S., Arvold, N. D., Harsh, G. R., Steeg, P. S., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0055-y · Cited by 1,034
Clinical relevance of tumour-associated macrophages
Pittet, M. J., Michielin, O., & Migliorini, D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00620-6 · Cited by 731
Integrating oncolytic viruses in combination cancer immunotherapy
Bommareddy, P. K., Shettigar, M., & Kaufman, H. L. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0014-6 · Cited by 704
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Naimi, A., Mohammed, R. N., Raji, A., Chupradit, S., Yumashev, A. V., Suksatan, W., Shalaby, M. N., Thangavelu, L., Kamrava, S., Shomali, N., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00854-y · Cited by 507
Oncolytic viruses as engineering platforms for combination immunotherapy
Twumasi-Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C., & Nelson, B. H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0009-4 · Cited by 417
Metadata
- Authors
- Samson, A., Scott, K. J., Taggart, D., West, E. J., Wilson, E., Nuovo, G. J., Thomson, S., Corns, R., Mathew, R. K., Fuller, M. J., Kottke, T. J., Thompson, J. M., Ilett, E. J., Cockle, J. V., van Hille, P., Sivakumar, G., Polson, E. S., Turnbull, S. J., Appleton, E. S., Migneco, G., Rose, A. S., Coffey, M. C., Beirne, D. A., Collinson, F. J., Ralph, C., Alan Anthoney, D., Twelves, C. J., Furness, A. J., Quezada, S. A., Wurdak, H., Errington-Mais, F., Pandha, H., Harrington, K. J., Selby, P. J., Vile, R. G., Griffin, S. D., Stead, L. F., Short, S. C., & Melcher, A. A.
- Venue
- Science Translational Medicine
- Published
- 2018-01-03
- Volume
- 10
- Issue
- 422
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2781931068
- Cited by
- 373
- References
- 53
- FWCI
- 27.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.